

Phase III placebo-controlled double-blind randomized trial of pegfilgrastim to reduce the risk of febrile neutropenia in breast cancer patients receiving docetaxel/cyclophosphamide chemotherapy

*Supportive Care in Cancer*

Y. Kosaka, Y. Rai, N. Masuda, T. Takano, T. Saeki, S. Nakamura, R. Shimazaki, Y. Ito, Y. Tokuda, K. Tamura

**Corresponding Author:** Yoshimasa Kosaka, Kitasato University School of Medicine, Sagami-hara, Japan;

E-mail: y-kosaka@med.kitasato-u.ac.jp

**Online Resource 1** Hematologic adverse events

Event/Grade <sup>a</sup>	First chemotherapy cycle				All chemotherapy cycles			
	Pegfilgrastim		Placebo		Pegfilgrastim		Placebo	
	(n = 173)		(n = 173)		(n = 173)		(n = 173)	
	n	%	n	%	n	%	n	%
Neutropenia								
Grade 3	7	4	2	1	15	9	0	0
Grade 4	3	2	171	99	7	4	173	100
Leukopenia								
Grade 3	3	2	101	58	8	5	86	50
Grade 4	1	1	68	39	1	1	86	50
Lymphopenia								
Grade 3	0	0	5	3	36	21	13	8
Grade 4	0	0	0	0	9	5	2	1

<sup>a</sup> Adverse events are graded according to the National Cancer Institute's Common Toxicity Criteria (version 4.0).